ALLK - Allakos falls as lead asset offers mixed results in late-stage trial

• The shares of clinical-stage biotech Allakos ( NASDAQ: ALLK ) dropped ~12% in the pre-market Friday after the company announced mixed results from its Phase 3 trial for lead asset lirentelimab in eosinophilic duodenitis ((EoD)), an inflammatory condition in the gastrointestinal tract.
• The randomized, double-blind study involved 93 biopsy-confirmed eosinophilic duodenitis patients who received monthly lirentelimab or placebo.
• The trial met its histologic co-primary endpoint but failed to achieve the statistical significance on the patient-reported symptomatic co-primary endpoint for the intent to treat (ITT) population, ALLK said.
• The company added that similar results were seen in a prespecified subpopulation that excluded certain patients whose conditions could cofound patient reported symptomatic endpoint.
• ALLK said it is not planning to conduct additional studies on eosinophilic gastrointestinal diseases as of now.

• Read more on the upcoming milestones for the company as announced with its Q2 2022 results.

For further details see: